{"cluster": 31, "subcluster": 23, "abstract_summ": "BACKGROUND: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS).In addition to physical therapists providing respiratory support in the ICU, the literature unequivocally supports the view that early intervention for ICU management of patients with ARDS secondary to COVID-19 needs to focus on reducing contributors to impaired long-term function, with direct attention paid to preventing or managing ICU-acquired weakness, deconditioning, and myopathies and neuropathies, in conjunction with respiratory care.METHODS: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS.We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study.Since ARDS is an entity not recognized in newborns, we want to emphasize neonatal ARDS diagnosis and underline that the combination of budesonide and surfactant may be a novel therapeutic option in the treatment of ARDS.Severe cases of coronavirus disease 2019 develop the acute respiratory distress syndrome, requiring admission to the ICU.", "title_summ": "Application of the respiratory \u201ccritical care-sub-critical care-rehabilitation integrated management model\u201d in severe stroke associated pneumoniaHyperoxemia and excess oxygen use in early acute respiratory distress syndrome: insights from the LUNG SAFE studyConsideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19.Rehabilitation and respiratory management in the acute and early post-acute phase.Endotracheal Surfactant Combined With Budesonide for Neonatal ARDSPotential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019Instant paper from the field\" on rehabilitation answers to the Covid-19 emergency.\"", "title_abstract_phrases": "Since ARDS is an entity not recognized in newborns, we want to emphasize neonatal ARDS diagnosis and underline that the combination of budesonide and surfactant may be a novel therapeutic option in the treatment of ARDS.Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019Severe cases of coronavirus disease 2019 develop the acute respiratory distress syndrome, requiring admission to the ICU.In addition to physical therapists providing respiratory support in the ICU, the literature unequivocally supports the view that early intervention for ICU management of patients with ARDS secondary to COVID-19 needs to focus on reducing contributors to impaired long-term function, with direct attention paid to preventing or managing ICU-acquired weakness, deconditioning, and myopathies and neuropathies, in conjunction with respiratory care.TRIAL REGISTRATION: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073Consideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19.This manuscript provides support for physical therapists to focus on the long-term, as well as the short-term, consequences of acute respiratory distress syndrome (ARDS) associated with COVID-19.We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study.Surfactant Combined With Budesonide for Neonatal ARDSAcute respiratory distress syndrome (ARDS) is a clinical condition characterized by acute diffuse inflammatory lung injury and severe hypoxemia."}